Pih3 Vaccination With Rix4414 Is Cost-Effective in a Belgian Setting

Fruytier, A; Schoor, J Van; Standaert, BA

doi:10.1016/s1098-3015(10)63361-x

Cited by 7 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Belgium provides a good opportunity to conduct such a comparison for rotavirus vaccination, as modelled estimates and observed data from a follow-up study of four years post-vaccination and two years pre-vaccination are available [18], [23]. In a previous paper on the impact of rotavirus vaccination on hospitalisation in Belgium, we reported that the observed reductions in rotavirus hospitalisations after vaccine introduction were greater than those predicted by modelling [18].…”

Section: Introductionmentioning

confidence: 95%

Impact of Rotavirus Vaccination on Hospitalisations in Belgium: Comparing Model Predictions with Observed Data

Standaert

Gómez²,

Raes

et al. 2013

PLoS ONE

View full text Add to dashboard Cite

BackgroundPublished economic assessments of rotavirus vaccination typically use modelling, mainly static Markov cohort models with birth cohorts followed up to the age of 5 years. Rotavirus vaccination has now been available for several years in some countries, and data have been collected to evaluate the real-world impact of vaccination on rotavirus hospitalisations. This study compared the economic impact of vaccination between model estimates and observed data on disease-specific hospitalisation reductions in a country for which both modelled and observed datasets exist (Belgium).MethodsA previously published Markov cohort model estimated the impact of rotavirus vaccination on the number of rotavirus hospitalisations in children aged <5 years in Belgium using vaccine efficacy data from clinical development trials. Data on the number of rotavirus-positive gastroenteritis hospitalisations in children aged <5 years between 1 June 2004 and 31 May 2006 (pre-vaccination study period) or 1 June 2007 to 31 May 2010 (post-vaccination study period) were analysed from nine hospitals in Belgium and compared with the modelled estimates.ResultsThe model predicted a smaller decrease in hospitalisations over time, mainly explained by two factors. First, the observed data indicated indirect vaccine protection in children too old or too young for vaccination. This herd effect is difficult to capture in static Markov cohort models and therefore was not included in the model. Second, the model included a ‘waning’ effect, i.e. reduced vaccine effectiveness over time. The observed data suggested this waning effect did not occur during that period, and so the model systematically underestimated vaccine effectiveness during the first 4 years after vaccine implementation.ConclusionsModel predictions underestimated the direct medical economic value of rotavirus vaccination during the first 4 years of vaccination by approximately 10% when assessing hospitalisation rates as compared with observed data in Belgium.

show abstract

Section: Introductionmentioning

confidence: 95%

Impact of Rotavirus Vaccination on Hospitalisations in Belgium: Comparing Model Predictions with Observed Data

Standaert

Gómez²,

Raes

et al. 2013

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Fifty-eight studies presented results of a Cost-Effectiveness Analysis (CEA b ). Outcome measures used in these CEAs included quality-adjusted life-years (QALYs) gained (22 studies), lives saved (27), disability-adjusted life years averted (25), admissions avoided (20), cases avoided (19) and life-years gained (13). The 22 studies reporting an incremental cost per qualityadjusted life years (QALY) gained are also classified as CostUtility Analyses (CUA) in Table 1.…”

Section: Search Methodologymentioning

confidence: 99%

“…In the Netherlands, results from the societal perspective also showed large variability: one study suggested that vaccination was cost-effective, 32 two that it was not cost-effective, 33,34 and one concluded that it depends on negotiated price. 35 In Belgium, results of different studies seemed relatively close, with cost per QALY gained varying between €51 000 (€63 100) for Rotarix 13 and €75,000 (€88 200) for RotaTeq 43,44 from the TPP perspective. In the US, results of Widdowson et al appeared as rather unfavorable to vaccination, with a base case ICER of $197 190 (€188 300) per life-year saved from a societal perspective.…”

Section: A Critical Literature Review Of Health Economic Evaluations mentioning

confidence: 97%

“…Although most studies suggest that the net costs of vaccination are positive, some concluded that vaccination is cost-saving from a societal perspective (Australia, 56 Belgium, 13 Italy, 29,30 UK, 39,41 and USA 73 ). However, the results of these studies were often contradicted by other results for the same countries.…”

Section: Assumptions and Inputs Of Economic Evaluationsmentioning

confidence: 99%

“…84 Only a few models accounted for RV seasonality, with a minimal impact, as based on sensitivity analyses. 13,19,20,36,50 Natural immunity. Natural immunity (also referred as acquired immunity) was also integrated in some models.…”

Section: Assumptions and Inputs Of Economic Evaluationsmentioning

confidence: 99%

See 2 more Smart Citations